Evaluation of the respiratory NeuMoDx™ Flu A-B/RSV/SARS-CoV-2 Vantage and Alinity m Resp-4-Plex assays

Quinton, Mikayla; Geahr, Melissa; Gluck, Linda; Jarrett, Junko; Mostafa, Heba H.

doi:10.1016/j.jcv.2022.105164

Cited by 7 publications

(6 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The overall results were excellent for influenza and SARS-CoV-2; the results regarding RSV were also very good, as only 3/46 samples with low viral load were not detected. In total, our results are in accordance with a recent study that evaluated the performance of the NeuMoDx Flu A-B/RSV/SARS-CoV-2 Vantage Assay compared to standard of care methods for the detection and differentiation of influenza A and B viruses, RSV, and SARS-CoV-2 with100% agreement [ 25 ]. Other commercial multiplex PCR tests targeting influenza A and B viruses, RSV, and SARS-CoV-2 that have been evaluated show similar performance to the NeuMoDx Flu A-B/RSV/SARS-CoV-2 Vantage Assay.…”

Section: Discussionsupporting

confidence: 89%

Clinical Performance Evaluation of the NeuMoDx Flu A-B/RSV/SARS-CoV-2 Vantage Assay

et al. 2022

View full text Add to dashboard Cite

SARS-CoV-2 infections may present with various symptoms that are similar to those of other respiratory diseases. For this reason, the need for simultaneous detection of at least RSV and influenza viruses together with SARS-CoV-2 was evident from the early stages of the pandemic. In the present study, we evaluated the clinical performance of the NeuMoDx™ Flu A-B/RSV/SARS-CoV-2 Vantage Assay against the conventional low-plex PCR utilized to detect influenza A-B, RSV, and SARS-CoV-2. There were 115 known positive clinical samples and 35 negative controls obtained from asymptomatic health-care workers included in the study; 25 samples were positive for influenza viruses, 46 for RSV, and 44 for SARS-CoV-2. The sensitivity, specificity, positive predictive value, and negative predictive value of the evaluated method for influenza and SARS-CoV-2 were 100%. The Spearman correlation coefficient was 0.586 (p < 0.05) for influenza and 0.893 (p < 0.05) for SARS-CoV-2. The sensitivity of the aforementioned assay for RSV was 93.47%; the specificity and the positive predictive value were 100%, and the negative predictive value was 92.10%, while the Spearman correlation coefficient was not applicable for the RSV. Overall, the assay under evaluation was shown to be a reliable alternative for the simultaneous detection of influenza viruses, RSV and SARS-CoV-2.

show abstract

Section: Discussionsupporting

confidence: 89%

Clinical Performance Evaluation of the NeuMoDx Flu A-B/RSV/SARS-CoV-2 Vantage Assay

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The first EUA-approved multiplex PCR assays for detecting these viruses was the Cepheid Xpert Xpress SARS-CoV-2/Flu/RSV Test, which has showed high accuracy and a good correlation with to standard-of-care tests. [101][102][103] Both the NeuMoDx™ Flu A-B/RSV/SARSCoV-2 Vantage Assay and the Alinity m Resp-4-Plex have also provided high sensitivity and accuracy as well, which may aid 104 The Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay and the PowerChek™ SARS-CoV-2, Influenza A&B Multiplex Real-time PCR Kit are both commercially available tools for detecting SARS-CoV-2, RSV, and influenza virus simultaneously in Korea. 105 In Australia, AusDiagnostics SARS-CoV-2, Influenza and the RSV 8-well assay have also shown efficacy in detecting these viruses at an intermediate concentration, which makes sample pooling a possible issue.…”

Section: Diagnostic Approach For Rsv In Covid-19 Eramentioning

confidence: 99%

The Impact of the COVID-19 Pandemic on Respiratory Syncytial Virus Infection: A Narrative Review

Chuang¹,

Lin²,

Wang³

et al. 2023

IDR

View full text Add to dashboard Cite

Respiratory syncytial virus (RSV) is one of the most common respiratory viruses. It not only affects young children but also the elderly and immunocompromised patients. After the emergence of SARS-CoV-2 and the corona virus disease 2019 (COVID-19) era, a dramatic reduction in RSV activity was found, which coincided with the implementation of public health and social measures (PHSMs). However, the correlation is more complicated than we initially thought. After PHSMs were gradually lifted, a seasonality shift and a delayed RSV outbreak with greater number of infected patients were found in numerous countries, such as Israel, Australia, South Africa, New Zealand, France, United States, and Japan. Several hypotheses and possible reasons explaining the interaction between SARS-CoV-2 and RSV were mentioned. Since RSV vaccinations are still under investigation, administration of palivizumab should be considered in high-risk patients. In the post-COVID-19 era, greater attention should be paid to a further resurgence of RSV. In this narrative review, we conducted a thorough review of the current knowledge on the epidemiology of RSV during the COVID-19 era, the out-of-season outbreak of RSV, and the data on co-infection with RSV and SARS-CoV-2.

show abstract

“…In the study, we tested the performance of the 4-Plex multiplex respiratory panel assay on the Alinity m automated molecular system for the simultaneous detection of Flu-A, Flu-B, hRSV and SARS-CoV-2 to determine the rate of overlooked Flu-A/B and hRSV infections in early 2022 and to investigate the epidemiological pattern of Flu-A/B and hRSV infections in the rst "post COVID-19" season. The Alinity m 4-plex was selected because it has good performance, high throughput, random access, semi-batch functionality, STAT (urgent) prioritization and the ability to load and run multiple different assays simultaneously, making it suitable for both inpatient and outpatient diagnostics [9][10][11][12][13]. Full integration with the LIS enables automatic sample recognition, ordering of tests/markers per sample, and release of results, minimizing the possibility of errors.…”

Section: Discussionmentioning

confidence: 99%

“…The analytical and clinical performance of the 4-Plex assay has been extensively reviewed in the past and showed good overall performance [10][11][12][13].…”

Section: Introduction Page 4/16mentioning

confidence: 99%

Influenza A, Influenza B, Human Respiratory Syncytial Virus and SARS-CoV-2 molecular diagnostics and epidemiology in the post COVID-19 era

Luštrek,

Cesar,

Suljič

et al. 2024

Preprint

View full text Add to dashboard Cite

Background The concurrent circulation of SARS-CoV-2 with other respiratory viruses is unstoppable and represents a new diagnostic reality for clinicians and clinical microbiology laboratories. Multiplexed molecular testing on automated platforms that focus on the simultaneous detection of multiple respiratory viruses in a single tube is a useful approach for current and future diagnosis of respiratory infections in the clinical setting. Methods Two time periods were included in the study: from February to April 2022, an early 2022 period, during the gradual lifting of non-pharmaceutical COVID-19 prevention measures in the country, and from October 2022 to April 2023, the 2022/23 respiratory infections season. We analysed a total of 1,918 samples in the first period and 18,131 respiratory samples in the second period using a multiplex molecular assay for the simultaneous detection of Influenza A (Flu-A), Influenza B (Flu-B), Human Respiratory Syncytial Virus (hRSV) and SARS-CoV-2. Results The results from early 2022 showed a strong dominance of SARS-CoV-2 infections with 1,267/1,918 (66.1%) cases. Flu-A was detected in 30/1,918 (1.6%) samples, hRSV in 14/1,918 (0.7%) samples, and Flu-B in 2/1,918 (0.1%) samples. Flu-A/SARS-CoV-2 co-detections were observed in 11/1,267 (0.9%) samples, and hRSV/SARS-CoV-2 co-detection in 5/1,267 (0.4%) samples. During the 2022/23 winter respiratory season, SARS-CoV-2 was detected in 1,738/18,131 (9.6%), Flu-A in 628/18,131 (3.5%), Flu-B in 106/18,131 (0.6%), and hRSV in 505/18,131 (2.8%) samples. Interestingly, co-detections were present to a similar extent as in early 2022. Conclusion The results show that the multiplex molecular approach is a valuable tool for the simultaneous laboratory diagnosis of SARS-CoV-2, Flu-A/B, and hRSV in hospitalized and outpatients. Infections with Flu-A/B, and hRSV occurred shortly after the non-pharmaceutical measures of COVID-19 were lifted, so a strong reoccurrence of various respiratory infections and co-detections in the post COVID-19 period was to be expected.

show abstract

Evaluation of the respiratory NeuMoDx™ Flu A-B/RSV/SARS-CoV-2 Vantage and Alinity m Resp-4-Plex assays

Cited by 7 publications

References 5 publications

Clinical Performance Evaluation of the NeuMoDx Flu A-B/RSV/SARS-CoV-2 Vantage Assay

Clinical Performance Evaluation of the NeuMoDx Flu A-B/RSV/SARS-CoV-2 Vantage Assay

The Impact of the COVID-19 Pandemic on Respiratory Syncytial Virus Infection: A Narrative Review

Influenza A, Influenza B, Human Respiratory Syncytial Virus and SARS-CoV-2 molecular diagnostics and epidemiology in the post COVID-19 era

Contact Info

Product

Resources

About